tucidinostat

Tucidinostat is an orally bioavailable benzamide-type histone deacetylase (HDAC) inhibitor that selectively targets class I HDAC enzymes (HDAC1, HDAC2, HDAC3) and class IIb HDAC10. It functions as a latency-reversing agent by promoting histone acetylation and chromatin relaxation, leading to transcriptional activation. In oncology, tucidinostat has demonstrated antineoplastic activity by inhibiting tumor cell proliferation and inducing apoptosis through inhibition of kinases in the PI3K/Akt and MAPK/Ras signaling pathways. It is approved in China for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan for adult T-cell leukemia-lymphoma (ATLL). Additionally, it is being investigated as part of strategies to cure HIV due to its ability to reactivate latent HIV via the NF-κB signaling pathway[1][5][7].

Brand names

EpidazaHiyasta

Other names

chidamide